ITOS vs. ETNB, OCUL, XNCR, SPRY, REPL, ELVN, MRVI, GYRE, ZYME, and COLL
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include 89bio (ETNB), Ocular Therapeutix (OCUL), Xencor (XNCR), ARS Pharmaceuticals (SPRY), Replimune Group (REPL), Enliven Therapeutics (ELVN), Maravai LifeSciences (MRVI), Gyre Therapeutics (GYRE), Zymeworks (ZYME), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs.
iTeos Therapeutics (NASDAQ:ITOS) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
In the previous week, 89bio had 10 more articles in the media than iTeos Therapeutics. MarketBeat recorded 14 mentions for 89bio and 4 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 0.95 beat 89bio's score of 0.25 indicating that iTeos Therapeutics is being referred to more favorably in the media.
97.2% of iTeos Therapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Comparatively, 2.8% of 89bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
iTeos Therapeutics has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
iTeos Therapeutics' return on equity of -20.11% beat 89bio's return on equity.
iTeos Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
iTeos Therapeutics presently has a consensus price target of $22.25, indicating a potential upside of 218.31%. 89bio has a consensus price target of $30.29, indicating a potential upside of 241.06%. Given 89bio's higher probable upside, analysts plainly believe 89bio is more favorable than iTeos Therapeutics.
89bio received 71 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 79.25% of users gave iTeos Therapeutics an outperform vote while only 64.20% of users gave 89bio an outperform vote.
Summary
iTeos Therapeutics beats 89bio on 12 of the 17 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 3/4/2025 by MarketBeat.com Staff
Free ITOS Stock Alerts